Objectif Stem cell research, and embryonic stem cell research in particular, offers the prospect of developing new therapies for serious or life-threatening diseases. But for the potential offered by stem cell research to be realized into therapeutic products, industrial or commercial investment is required. At the same time, embryonic stem cell research raises difficult and controverted moral questions which are reflected in the variety of moral perspectives and regulatory regimes already adopted or currently being developed in EU member States which vary from total prohibition to qualified authorization in varying forms and degrees. The diversity of legal regimes regulating embryonic stem cell research in Europe together with the subsidiary principle which devolves competency on legislation concerning ethical questions to members States, has created uncertainty as to the legal scope of the moral exclusion clause in Article 6 of Directive 98/44EC of 6 July 1998 on the legal protection of biotechnological inventions. Clarification on the scope of the Directive is essential to foster research and investment in Europe whilst ensuring that such research is conducted within clear ethical limits which address the concerns of society. The project aims to provide an analysis of the EU patent system, as applied to biotechnological inventions in general and to embryonic stem cell related technology in particular with a view to ascertain the legal effect of ethical or legal divergence on European patent law. The multi-faceted nature of the question raised requires the combined efforts of experts from different disciplines to contribute to the coordination, analysis and dissemination of knowledge in this area. The multidisciplinary character of the Consortium is intended to bring the required breadth and depth of expertise to bear on the project. Champ scientifique medical and health sciencesmedical biotechnologycells technologiesstem cellssocial scienceslaw Mots‑clés biotechnology comparative law human embryo human rights intellectual property medical law stem cells Programme(s) FP6-LIFESCIHEALTH - Life sciences, genomics and biotechnology for health: Thematic Priority 1 under the Focusing and Integrating Community Research programme 2002-2006. Thème(s) LSH-2003-3-4 - Stimulating exploitation LSH-2003-3-7 - EU Strategy for Life Sciences and Biotechnology Appel à propositions FP6-2003-LIFESCIHEALTH-I Voir d’autres projets de cet appel Régime de financement SSA - Specific Support Action Coordinateur THE UNIVERSITY OF NOTTINGHAM Contribution de l’UE Aucune donnée Adresse University Park NOTTINGHAM Royaume-Uni Voir sur la carte Liens Site web Opens in new window Coût total Aucune donnée Participants (4) Trier par ordre alphabétique Trier par contribution de l’UE Tout développer Tout réduire EUROPEAN FORUM FOR GOOD CLINICAL PRACTICE Belgique Contribution de l’UE Aucune donnée Adresse MAI, rue Washington 40 BRUSSELS Voir sur la carte Liens Site web Opens in new window Coût total Aucune donnée RENEURON LTD Royaume-Uni Contribution de l’UE Aucune donnée Adresse 10 Nugent Road, Surrey Research Park GUILDFORD Voir sur la carte Liens Site web Opens in new window Coût total Aucune donnée STOCKHOLM UNIVERSITY Suède Contribution de l’UE Aucune donnée Adresse Universitetsvagen 10 STOCKHOLM Voir sur la carte Liens Site web Opens in new window Coût total Aucune donnée UNIVERSITE DE MONTREAL Canada Contribution de l’UE Aucune donnée Adresse C.P. 6128 succ. Centre-ville MONTREAL (QUEBEC) Voir sur la carte Coût total Aucune donnée
